Menlo Therapeutics Inc

61 articles with Menlo Therapeutics Inc

• 

  BioSpace Movers & Shakers, March 27

  3/27/2020

  Pharma and life sciences companies from across the globe provide updates on their pipelines and business.

• Menlo Therapeutics Appoints Andrew Saik as Chief Financial Officer

  3/24/2020

  Menlo Therapeutics Inc. appointed Andrew Saik as Chief Financial Officer and Treasurer, effective March 23, 2020. Mr. Saik will report to David Domzalski, Chief Executive Officer, and will be responsible for leading the Company’s global finance operations, including, fi

• Menlo Therapeutics Provides a Business Update in the Context of COVID-19

  3/20/2020

  Menlo Therapeutics Inc. today provided a business update in the context of the developing situation with the COVID-19 (coronavirus) pandemic. At this time, Menlo does not anticipate any changes to key clinical and regulatory milestones in 2020, but is continuing to moni

• Menlo Reports Financial Results for Subsidiary Foamix Pharmaceuticals for Year Ended December 31, 2019

  3/12/2020

  Menlo Therapeutics Inc. today announced financial results for its wholly owned subsidiary, Foamix Pharmaceuticals.

• Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

  3/9/2020

  Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today the completion of its merger with Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix”) following the satisfaction of all closing conditions required by the merger agreement.

• Menlo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

  3/3/2020

  Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced financial results for the fourth quarter and year ended December 31, 2019 and reviewed business highlights. 

• 

  Clinical Catch-Up: February 24-28

  3/2/2020

  The month of February ended with a flurry of clinical trial announcements. Here’s a look.

• Menlo Therapeutics to Host Conference Call Tomorrow to Discuss Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin

  2/26/2020

  Menlo Therapeutics Inc., a late-stage biopharmaceutical company, announced it will host a conference call and webcast on Wednesday, February 26, 2020 at 8:30 am ET to discuss results from the Phase 2 trial of serlopitant in patients with chronic pruritus of unknown origin.

• Menlo Therapeutics Announces Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown OriginMenlo to Host Conference Call Today at 8:30 AM Eastern Time; Foamix’s CEO David Domzalski will be Available for Q&A

  2/26/2020

  REDWOOD CITY, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced results from its Phase 2 clinical trial evaluating the safety and efficacy of once daily oral serlopitant for the treatment of chronic pruritus (itch) of unknown origin (CPUO). The trial, which included 233 patients, did not meet its primary endpoint to show a statistically significant reduction in pruritus in patients treated with serlopitant

• 

  Clinical Catch-Up: February 3-7, 2020

  2/10/2020

  Although it was a relatively slow week for clinical trial updates, there were still a number of announcements. Here’s a look.

• Foamix and Menlo Announce Shareholder Approval of Proposed MergerTransaction on Track to Close in early March 2020

  2/6/2020

  Foamix Pharmaceuticals Ltd. and Menlo Therapeutics Inc. announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder and stockholder proposals necessary to complete the previously announced merger at their respective shareholder / stockholder meetings.

• Menlo Therapeutics Announces Publication of Phase 2 Results for Serlopitant for the Treatment of Pruritus Associated with Psoriasis in the Journal of the American Academy of Dermatology

  2/5/2020

  Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced the publication of the company’s Phase 2 trial of serlopitant for the treatment of pruritus associated with psoriasis in the Journal of the American Academy of Dermatology (JAAD).

• Menlo Therapeutics CEO to Participate in Fireside Chat at the Piper Jaffray 31st Annual Healthcare Conference

  11/27/2019

  Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, chief executive officer of Menlo Therapeutics, will provide a corporate update via a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference to be held in New York on December 03, 2019 at 4:00 pm ET.

• Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

  11/11/2019

  Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assets

• 

  Foamix and Menlo Therapeutics Combine to Form Single Dermatology Company

  11/11/2019

  The merged company will be led by David Domzalski, current chief executive officer of Foamix. It will be headquartered in New Jersey.
• 

  Clinical Catch-Up: October 28-Nov 1

  11/4/2019

  Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look.

• Menlo Therapeutics Reports 3Q 2019 Financial Results and Provides Program Updates- Pivotal Data from two Phase 3 Trials in Prurigo Nodularis Expected March/April 2020 and Phase 2 Trial Results in Chronic Pruritus of Unknown Origin Expected Janu

  10/31/2019

  Menlo Therapeutics Inc., a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus, announced financial results for the third quarter ended September 30, 2019 and provided an update on its clinical development programs.

• Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials of Serlopitant in Prurigo Nodularis

  10/29/2019

  Menlo Therapeutics Inc. announced that it has completed enrollment of patients in its two Phase 3 clinical trials evaluating the safety and efficacy of once daily oral serlopitant for the treatment of pruritus associated with prurigo nodularis The U.S. and European Phase 3 trials enrolled 285 and 295 patients, respectively.

• Menlo Therapeutics to Host Investor Day October 29, 2019

  10/22/2019

  Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company, announced that the company will host an Investor Day on Tuesday, October 29th, 8:00–11:00 am ET.

• 

  Clinical Catch-Up: October 7-11

  10/14/2019

  It was a busy week for clinical trial announcements. Here’s a look.